Pension Plans’ Suit Against Oppenheimer Dismissed

March 1, 2013 (PLANSPONSOR.com) – A federal district court has dismissed a lawsuit filed by two Massachusetts municipal pension boards alleging Oppenheimer & Co. made mis-statements about one of its mutual funds.

The retirement boards for the cities of Brockton and Quincy sued Oppenheimer Global Resource Private Equity Fund I, L.P. (OGR Fund), a closed-end fund of private equity funds with a 10-plus-year life, alleging actionable mis-statements in the materials used to solicit investments in the fund. The U.S. District Court for the District of Massachusetts ruled that the retirement boards failed to state a claim because they invested in the OGR Fund through private transactions, so Section 12(a)(2) of the Securities Act does not apply.  

According to the court’s opinion, section 12(a)(2) makes liable any person who “offers or sells a security . . . by means of a prospectus or oral communication, which includes an untrue statement of a material fact.” The court cited Gustafson v. Alloyd Co., in which the U.S. Supreme Court held that the statutory term “prospectus” refers only to “a document soliciting the public to acquire securities.” That case involved a private transaction in which three sole shareholders sold their entire interests in a privately held corporation to a corporate buyer. The buyer later argued that the private stock purchase agreement was a “prospectus,” and so the sellers should be liable under section 12(a)(2) for material mis-statements therein.  

Never miss a story — sign up for PLANSPONSOR newsletters to keep up on the latest retirement plan benefits news.

However, the Supreme Court disagreed, looking to Section 10 of the Securities Act, which requires every “prospectus” to include “the information contained in the registration statement” for the security being offered or sold. 

In the present case, the complaint alleges that the limited partnership units the plaintiffs purchased “were not registered under applicable securities laws and were offered privately, pursuant to an exemption from registration under Section 4(2) of the Securities Act of 1933.Because the limited partnership units were purchased through a private placement rather than a public offering, Section 12(a)(2) does not apply, the Massachusetts court concluded.  

The retirement boards alleged that the OGR Fund used its inflated figures to aggressively solicit potential investors, misleading them into believing that the fund was showing a profit when in fact it was operating at a loss. They sued the defendants under Section 12(a)(2) of the Securities Act, claiming that the defendants’ solicitation materials contained material mis-statements. They also alleged that the defendants are liable as “controlling persons” under Section 15 of the Securities Act.  

The court found that since Section 12(a)(2) does not apply, the boards’ Section 15 claims also do not apply.  

The court’s opinion is here.

Oppenheimer & Co. is not associated with OppenheimerFunds Inc.

Conn. Retirement Funds Can Sue Amgen

March 1, 2013 (PLANSPONSOR.com) The Supreme Court of the United States issued an opinion allowing the Connecticut Retirement Plans and Trust Funds to assert claims in a securities fraud case against Amgen.

The opinion affirmed a lower court order certifying that the Connecticut Retirement Plans and Trust Funds can assert claims in the case on behalf of a class of injured investors. Writing for the six-justice majority, Justice Ruth Bader Ginsburg rejected Amgen’s arguments that the District Court was required to resolve at the class certification stage the issue of whether Amgen’s alleged misrepresentations were “material” to investors, according to an announcement by State Treasurer Denise L. Nappier and Connecticut Attorney General George Jepsen. The court held that this is an inquiry into the merits of the case that more properly should be resolved on a motion for summary judgment or at trial.    

The decision clears the way for the Connecticut Retirement Plans and Trust Funds to return to the Central District of California and continue pursuing claims against Amgen on behalf of all investors injured by Amgen’s alleged fraud.   

For more stories like this, sign up for the PLANSPONSOR NEWSDash daily newsletter.

The funds allege that California-based biotech giant Amgen Inc. (AMGN) and certain of its former executives contrived to mislead the investing public about the true value of Amgen stock through a series of mis-statements and omissions about two of Amgen’s flagship products, Epogen and Aranesp. The case was first filed in 2007, following a series of public disclosures of negative information about the products that caused significant decreases in the price of Amgen’s stock.  

Former participants of the Amgen Retirement and Savings Plan and the Retirement and Savings Plan for Amgen Manufacturing Ltd. filed a lawsuit with similar claims in 2010. That case was dismissed (see “Court Dismisses Claims against Amgen in Stock Drop Case”).

«